Overview
One-liner
The Intelligence layer for Drug Manufacturing
Why it's interesting
Market trends shaping AbInitio Bio
- 1AI-designed molecules entering clinic faster but readouts still TBD
- 2TechBio platforms shifting from tools to wholly-owned pipelines
- 3GLP-1 manufacturing bottlenecks creating supply-chain opportunities
- 4Targeted protein degraders and radioligands the hottest modalities
- 5China biotech in-licensing reshaping US pharma BD
- 6Decentralized trials finally working post-COVID infrastructure investment
Insights · email required
Unlock the 6 trends behind AbInitio Bio
Enter your email to read every market insight across all 400 startups — free.
Recommended reading & listening
Related insights & creators
- Newsletter · new-media.coOwl Posting
Abhishaike Mahajan on bio, ML for drug discovery, and TechBio.
- Mar 2026 · neweconomies.coAI Infrastructure Boom: GPT-5.4, $500M Chips, Brain Implants
$230M brain-implant bet, OpenAI's new model, Netflix's AI acquisition.
- Newsletter · new-media.coOut-of-Pocket
Nikhil Krishnan on healthcare business models, payors, and AI.
- Jun 2024 · neweconomies.coAI Agents
The rise of autonomous AI agents and the new application layer.